HER2 Breast Cancer

Latest News

Microscopic visualization of breast cancer cells | Image Credit: © seoashi - stock.adobe.com

GLSI-100 Granted Fast Track Designation for HER2-Positive Breast Cancer

By Alexandra Gerlach, Associate Editor

September 11th 2025

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

3D visualization of an antibody-drug conjugate. | Image Credit: © Alpha Tauri 3D - stock.adobe.com

Patritumab Deruxtecan Meets Primary End Point in ICARUS-BREAST01 Trial

By Alexandra Gerlach, Associate Editor

September 9th 2025

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

Breast cancer cells | Image Credit: © sknab - stock.adobe.com

Abemaciclib Plus Endocrine Therapy Improves Survival in Patients With HR+/HER2– Breast Cancer

By Alexandra Gerlach, Associate Editor

August 28th 2025

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

Metformin prescription bottle | Image Credit: © Sherry Young - stock.adobe.com

Metformin Shows Survival Benefit in Patients With HER2-Positive Breast Cancer

By Alexandra Gerlach, Associate Editor

August 24th 2025

The study results could help bolster metformin as a potentially attractive option for patients with HER2-positive breast cancer.

Vibrant Green Mitragyna Speciosa Plantation Leaves | Image Credit: Yonus | stock.adobe.com

Natural Alkaloids From Mitragyna speciosa, 7-OH Show Potential as Novel HER2 Inhibitors in Breast Cancer

By Danielle Valletti, Assistant Editor

August 22nd 2025

A new study found that the natural alkaloids mitragynine and 7-hydroxymitragynine from Mitragyna speciosa showed stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer.

...

3 4 5 6 7

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777